Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: Implications for when to initiate therapy

Journal of Infectious Diseases

Volumn 190, Issue 6, 2004, Pages 1046-1054

  Wang, Cunlin ^a   Vlahov, David ^a,c   Galai, Noya ^a   Bareta, Joseph ^a   Strathhdee, Steffanie A ^a   Nelson, Kenrad E ^a   Sterling, Timothy R ^a,b,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; SERODIAGNOSIS; SURVIVAL RATE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 4444227111     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422848     Document Type: Article

References (41)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
2. The CASCADE Collaboration. Concerted action on seroconversion to AIDS and death in Europe: survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-9.
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
5. Anastos K, Kalish LA, Hessol N, et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. AIDS 1999; 13:1717-26.
6. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77.
7. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
8. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents - July 14, 2003. Available at: http://www.aidsinfo.nih.gov /guidelines. Accessed February 2004.
9. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288:222-35.
10. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-7.
11. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-7.
12. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002; 155:760-70.
13. Anastos K, Barron Y, Miotti P, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002; 162:1973-80.
14. Jaggy C, von Overbeck J, Ledergerber B, etc. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362:877-8.
15. Bargagli AM, Sperati A, Davoli M, Forastiere F, Perucci CA. Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97. Addiction 2001; 96:1455-63.
16. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707-15.
17. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109: 75-100.
18. Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12:462-8.
19. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113:91-8.
20. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17):1-19.
21. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996; 124:999-1005.
22. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14:1707-23.
23. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-6.
24. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV-infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999; 53:4-8.
25. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280:547-9.
26. 6/L. AIDS 2002; 16:1371-81.
27. + cell strata. Ann Intern Med 2003; 138:620-6.
28. 3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003; 36:812-5.
29. Prins M, Sabin CA, Lee CA, et al. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000; 14:1829-37.
30. Seaman SR, Brettle RP, Gore SM. Pre-AIDS mortality in the Edinburgh City Hospital HIV Cohort. Stat Med 1997; 16:2459-74.
31. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-71.
32. Poole WK, Fulkerson W, Lou Y, et al. Overall and cause-specific mortality in a cohort of homo-/bisexual men, injecting drug users, and female partners of HIV-infected men. AIDS 1996; 10:1257-64.
33. Prins M, Hernandez Aguado IH, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11:1747-56.
34. Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective study of infective endocarditis among injection drug users. J Infect Dis 2002; 185:1761-6.
35. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
36. + T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-7.
37. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
38. Haynes BF, Hale LP, Weinhold KJ, et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 1999; 103:453-60.
39. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
40. Wood E, Hogg RS, Yip B, et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188:1421-5.
41. Hsu LC, Vittinghoff E, Katz MH, et al. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001; 28:345-50.